CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
RAD001 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00630344
NCT00630344Phase 2Completed
CompareCT.gov

A Phase II Trial of RAD001 and Bicalutamide for Androgen Independent Prostate Cancer

Dana-Farber Cancer Institute·interventional·Posted Mar 7, 2008·Updated Dec 8, 2017

In Brief

A Phase 2 clinical trial evaluating RAD001 and Bicalutamide for Prostate Cancer. Completed, enrolled 36 participants across 2 sites.

Detailed Summary

In the treatment of castration-resistant prostate cancer (CRPC), therapies will long response durations remain elusive as a result of the inherent ability of prostate cancer cells to develop iterative resistance. The goal of this study is to learn if the study drug RAD001 together with Bicalutamide can slow the growth of prostate cancer. The safety of the combination will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsBeth Israel Deaconess Medical Center, Novartis Pharmaceuticals

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 7, 2008
Enrollment StartFeb 1, 2008
Primary CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 18.3 years ago

Interventions

RAD001drug

Bicalutamidedrug